Carlsmed, INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NASDAQ

6 Nov 2025

CARL

10-Q: Carlsmed Q3 2025: Revenue Soars 98% Post-IPO, Cervical Launch Nears

Carlsmed, Inc. reports significant revenue growth and gross margin improvement in Q3 2025, driven by increased adoption of its aprevo Technology Platform and successful IPO, despite continued operating losses.

NASDAQ

28 Aug 2025

CARL

Carlsmed, INC

10-Q: Carlsmed Reports Near 100% Revenue Growth, Boosted by IPO

Carlsmed, Inc. announced significant revenue growth and a successful $93.5 million IPO, while continuing to expand its AI-enabled spine surgery platform and address increasing net losses.